Yahoo! FinanceFinance Home - My Yahoo - Yahoo! - Help 

Friday, November 27, 2009, 5:59PM ET - U.S. Markets closed early today. Dow Down 1.48% Nasdaq Down 1.73%
AVI Biopharma, Inc. (AVII)At 1:00PM ET: 1.46  Down 0.02 (1.35%)  
MORE ON AVII
Quotes
Charts
News & Info
Company
HereProfile
Analyst Coverage
Ownership
Financials

ProfileGet Profile for:
AVI Biopharma, Inc.
3450 Monte Villa Parkway
Suite 101
Bothell, WA 98021
United States - Map
Phone: 425-354-5038
Web Site: http://www.antivirals.com

DETAILS 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:83

BUSINESS SUMMARY 
AVI BioPharma, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products based on antisense and cancer immunotherapy technology. The company’s products under various development stages comprise AVI-4658, a Phase I human clinical trial product to restore, prevent, or slow deterioration of muscle function; AVI-5038, a preclinical stage product to skip exon 50 and restore a range of associated mutations; AVI-5126, a Phase II clinical trial product for the treatment of cardiovascular restenosis; and AVI-6002 and AVI—6003, which are in Phase I clinical trials to treat diseases caused by Dengue, Ebola, Marburg, and Junín viruses. It has strategic alliances with Chiron Corporation; Cook Group Incorporated; Ercole Biotech, Inc.; Eleos Inc.; Charley’s Fund, Inc.; and the United States Department of Defense. The company was founded in 1980 and is based in Corvallis, Oregon.
Key Statistics

COMPANY WEBSITES 
  • Home Page
  • Search Yahoo! for:
    More on AVI Biopharma, Inc.


    CORPORATE GOVERNANCE 
    AVI Biopharma, Inc.'s Corporate Governance Quotient (CGQ®) as of 6-Nov-09 is better than 30.4% of Russell 3000 companies and 34.6% of Pharmaceuticals, Biotechnology & Life Sciences companies.
    Brought to you by Institutional Shareholder Services.

    KEY EXECUTIVES 
     PayExercised
    Dr. Leslie Hudson Ph.D., 61
    Chief Exec. Officer, Pres, Principal Operating Officer
    $ 607.00KN/A
    Mr. J. David Boyle II, 55
    Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec.
    $ 166.00KN/A
    Dr. Patrick L. Iversen Ph.D., 53
    Sr. VP of Strategic Alliances
    N/A N/A
    Dr. Dwight D. Weller Ph.D., 58
    Sr. VP of Chemistry & Manufacturing
    N/A N/A
    Dr. Ryszard Kole Ph.D., 62
    Sr. VP of Discovery Research
    N/A N/A
    Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
    View Insiders


    Add to My Portfolio Add to Portfolio    Set Alert Set Alert    Email to a Friend Email to a Friend
    Get Profile for Another Symbol: Symbol Lookup
    Annual ReportsSector Analysis